Clinical Trial Update: Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This clinical trial update summarizes the Phase 1 safety results of the recombinant human monoclonal antibody rhuMAb 2C4 in patients with advanced solid tumors.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• rhuMAb 2C4

Snippet

Sponsor: Genentech, Inc. | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2015-07-27